论文部分内容阅读
本研究目的在于观察α－骨化醇（ＢＯＮＥ－ＯＮＥ）对糖尿病合并骨质疏松长期治疗的安全性和有效性。绝经后女性Ⅱ型糖尿病合并骨质疏松２９例，随机选择其中２０例为糖尿病治疗组，９例为糖尿病对照组，年龄等相匹配老年女性骨质疏松１０例（老年治疗组）共三组病人进行６个月药物治疗，糖尿病治疗组及老年治疗组服用α－骨化醇剂量为０．５μｇ·ｄ－１。研究结果：糖尿病与老年治疗组在治疗３个月、６个月后骨密度增高、骨形成指标增加（ＢＰＧ）、骨吸收指标减少（Ｃｒｏｓｓｌａｐ／Ｃｒ）和骨痛缓解率明显增加，分别是：骨密度由０．３２３±０．０１，０．２９７±０．０３（ｇ／ｃｍ２）升至０．４１５±０．０６，０．３７８±０．０３（ｇ／ｃｍ２）；ＢＧＰ由１０．１９±０．７９，９．２４±１．２６（ｍｇ·Ｌ－１）升至１５．８９±０．１２，１４．５５±１．１２（ｍｇ·Ｌ－１）；骨吸收指标Ｃｒｏｓｌａｐ／Ｃｒ由３６３．７±９１．３，４２０．２±１０７．９（μｇ·ｍｍｏｌ－１）减至２２６．９±５３．７，１６２．１４±５３．７（μｇ·ｍｍｏｌ－１）但两组间无显著差异，糖尿病对照组无变化。研究结果表明：糖尿病合并骨质疏松病人在良好控制血糖基础上服用α－骨化醇?
The aim of this study was to investigate the safety and efficacy of BONE-ONE in the long-term treatment of diabetic patients with osteoporosis. Postmenopausal women with type Ⅱ diabetes mellitus and osteoporosis in 29 cases were randomly selected 20 cases of diabetes treatment group, 9 cases of diabetic control group, age and other elderly women with osteoporosis in 10 cases (elderly treatment group) a total of three groups of patients Six months of drug treatment, diabetes treatment group and the elderly treatment group taking α-ossified metal dose of 0.5μg · d-1. Results: The bone mineral density, bone formation index (BPG), reduction of bone resorption index (Crosslap / Cr) and bone remission rate were significantly increased in diabetic and geriatric treatment groups at 3 months and 6 months after treatment: The BMD increased from 0.323 ± 0.01 and 0.297 ± 0.03 (g / cm2) to 0.415 ± 0.06 and 0.378 ± 0.03 (g / cm2), respectively. 19 ± 0.79, 9.24 ± 1.26 (mg · L-1) increased to 15.89 ± 0.12,14.55 ± 1.12 (mg · L-1) lap / Cr decreased from 363.7 ± 91.3, 420.2 ± 107.9 (μg · mmol-1) to 226.9 ± 53.7, 162.14 ± 53.7 (μg · mmol-1) However, no significant difference between the two groups, no change in the diabetic control group. The results show that: diabetes patients with osteoporosis in the good control of blood glucose based on the use of α-ossified?